Susquehanna International Group
VRCA icon

Susquehanna International Group’s Verrica Pharmaceuticals VRCA Stock Holding History

Susquehanna International Group’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,960
Closed -$370K – 13985
2021
Q3 		$370K Buy
+2,960
New +$332K ﹤0.01% 10104

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SA
Sovran Advisors San Diego, California $1.34B AUM 21.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Susquehanna International Group's VRCA Position: Q3 2025 in Review

Susquehanna International Group sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 6,659 shares — an estimated $35.3K sold.

Susquehanna International Group first reported a position in VRCA in Q1 2021 and held it in 14 quarters. The position peaked at $885K in Q1 2023. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

  • Susquehanna International Group reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 6,659 Verrica Pharmaceuticals shares in Q3 2025, an estimated $35.3K.
  • Susquehanna International Group first reported a position in Verrica Pharmaceuticals in Q1 2021 and held it in 14 quarters.
  • Susquehanna International Group's Verrica Pharmaceuticals position peaked at $885K in Q1 2023.
  • 34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.